Dexcom (DXCM) Net Equity Issued and Repurchased (2010 - 2026)

Dexcom (DXCM) has reported Net Equity Issued and Repurchased for 17 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased fell 10.56% year-over-year to $12.7 million; the TTM figure through Jun 2026 stood at $26.6 million (down 8.28% YoY), while the FY2025 annual figure was $28.1 million, changed 0.35% from the prior year.
• Net Equity Issued and Repurchased retreated to $12.7 million in Q1 2026 per DXCM's latest filing, from $13.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $14.8 million in Q3 2024 and bottomed at $10.1 million in Q1 2022.
• Historically, Net Equity Issued and Repurchased has averaged $13.1 million across 5 years, with a median of $13.4 million in 2024.
• Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased grew 21.78% — and 2026, when it decreased 10.56%.
• Dexcom's Net Equity Issued and Repurchased stood at $12.4 million in 2022, then rose by 15.32% to $14.3 million in 2023, then rose by 3.5% to $14.8 million in 2024, then fell by 6.08% to $13.9 million in 2025, then declined by 8.63% to $12.7 million in 2026.
• Business Quant data shows DXCM's Net Equity Issued and Repurchased at $12.7 million in Q1 2026, $13.9 million in Q3 2025, and $14.2 million in Q1 2025.